(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide (Compound)

Description: A compound in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

Source	Relation	Target	Evidence
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 4 Protein (Entity type)	Ki
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 1 Protein (Entity type)	Ki
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 2 Protein (Entity type)	Ki
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 3 Protein (Entity type)	Ki
(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,37S,Z)-14-((1H-indol-3-yl)methyl)-5-(2-amino-2-oxoethyl)-2,17-bis(4-aminobutyl)-37-(2-((S)-2-aminopropanamido)acetamido)-8,11,23-tribenzyl-20,26-bis((R)-1-hydroxyethyl)-29-(hydroxymethyl)-3,6,9,12,15,18,21,24,27,30,38-undecaoxo-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclooctatriacont-34-ene-32-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 5 Protein (Entity type)	Ki